Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.